Telix Pharmaceuticals Limited (TLX)

Telix Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Apr 25, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	6,173	5,098	2,224	1,563	1,606	818
Market Cap Growth	129.18%	129.18%	42.30%	-2.70%	96.45%	196.48%
Enterprise Value	6,090	5,038	2,144	1,482	1,572	801
Last Close Price	18.80	15.40	-	-	-	-
PE Ratio	199.81	165.02	626.21	-	-	-
PS Ratio	12.74	10.52	6.49	14.37	290.85	203.33
PB Ratio	17.55	14.50	21.91	28.75	1023.78	13.41
P/TBV Ratio	65.59	54.17	83.14	109.40	-	53.46
P/FCF Ratio	675.97	578.16	229.72	-	-	619.12
P/OCF Ratio	231.81	191.44	136.63	-	-	540.78
EV/Sales Ratio	12.57	10.39	6.26	13.62	284.54	199.24
EV/EBITDA Ratio	112.37	92.95	55.00	-	-	-
EV/EBIT Ratio	120.17	99.41	60.60	-	-	-
EV/FCF Ratio	666.95	571.37	221.37	-	-	606.68
Debt / Equity Ratio	1.02	1.02	0.12	0.13	1.18	0.03
Debt / EBITDA Ratio	6.47	6.47	0.30	-	-	-
Debt / FCF Ratio	40.81	40.81	1.23	-	-	1.29
Asset Turnover	0.82	0.82	1.52	0.88	0.06	0.04
Inventory Turnover	10.79	10.79	15.36	10.92	1.25	3.45
Quick Ratio	2.60	2.60	1.18	1.90	1.13	4.62
Current Ratio	2.78	2.78	1.41	2.03	1.25	4.69
Return on Equity (ROE)	13.92%	13.92%	4.55%	-253.34%	-198.36%	-60.21%
Return on Assets (ROA)	5.33%	5.33%	9.81%	-25.37%	-37.95%	-23.64%
Return on Capital (ROIC)	7.78%	7.78%	25.26%	-97.35%	-118.20%	-40.13%
Return on Capital Employed (ROCE)	6.90%	6.90%	21.50%	-	-	-
Earnings Yield	0.50%	0.61%	0.16%	-4.53%	-3.64%	-4.23%
FCF Yield	0.15%	0.17%	0.43%	-3.09%	-2.75%	0.16%
Buyback Yield / Dilution	-6.64%	-6.64%	-4.21%	-10.08%	-9.69%	-10.21%

Updated Feb 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q